Compare PVL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PVL | ACRV |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 67.2M |
| IPO Year | N/A | 2022 |
| Metric | PVL | ACRV |
|---|---|---|
| Price | $1.66 | $1.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 65.1K | ★ 415.4K |
| Earning Date | 03-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.43% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $1.20 |
| 52 Week High | $2.04 | $3.56 |
| Indicator | PVL | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 65.74 |
| Support Level | $1.61 | $1.62 |
| Resistance Level | $1.91 | $2.02 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 32.00 | 74.07 |
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.